Fujifilm Holdings Stock Earnings Reports

FUJIFILM reported Q1 FY2026 revenue of JPY749.5 billion and operating income of JPY75.3 billion — both record highs for a Q1 — while net income was JPY53.8 billion (impacted by FX losses). On a currency-neutral basis revenue grew ~4.5% and operating income ~35.1% YoY. Strength came from Bio CDMO, semiconductor materials, and imaging; healthcare faced softness in medical materials (notably film demand in China). Management incorporated an assessed JPY6 billion negative impact from recent US reciprocal tariffs into the full-year forecast but kept prior guidance unchanged (targeting record revenue JPY3.28 trillion, operating income JPY331 billion, net income JPY262 billion). Key operational updates: Bio CDMO secured long-term contracts totalling ~USD2 billion for US second-phase tanks (FY2028 start), Denmark expansion progressing, and unit pricing on recent CDMO contracts is higher than initially projected with inflation clauses. Product/technology highlights include a PFAS-free negative-tone ArF immersion photoresist (demonstrated at 28nm with imec) and expansion of refurbished MFD manufacturing (new Philippines site). Imaging performed very strongly (instax and digital cameras), and electronics saw improved margins driven by semiconductor materials (CMP slurry and mix improvement). Management reiterated dividend guidance (JPY70) and emphasized supply-chain, pricing, and cost measures to mitigate tariff effects while pursuing growth in alternative markets (India, Middle East, Central Asia, Africa).